SEC Filings

AVEXIS, INC. filed this Form S-1/A on 02/01/2016
Entire Document

Table of Contents

    portion of Mr. Carbona's stock option awards, as computed in accordance with ASC 718 as of the modification date on April 22, 2015, that were accelerated in connection with the termination of Mr. Carbona's employment, to which each of Mr. Harkey and Dr. Genecov had the right to purchase under the terms of the Stock Purchase and Option Agreement described in "Executive Compensation—Equity-Based Awards—Stock Purchase and Option Agreement" below. See "Executive Compensation—Payments upon Termination or Change in Control" below for a discussion of the acceleration of the 53,820 unvested stock options held by Mr. Carbona at the time of the termination of his employment. We determined that the acceleration of vesting was a Type III modification pursuant to ASC 718. Therefore, we recognized the amount immediately since the awards did not require further service.

As of December 31, 2015, the number of unvested stock awards held by Dr. Kaspar was 1,750,794. Dr. Kaspar did not have any outstanding option awards as of December 31, 2015.

This amount represents cash consulting fees paid to Dr. Kaspar pursuant to his consulting agreement.

Mr. Koh joined the board in June 2015.

Mr. Verwiel joined the board in December 2015.


© AveXis, Inc. All Rights Reserved.